Foghorn Therapeutics (NASDAQ: FHTX) furnishes September 2025 investor deck

Rhea-AI Filing Summary

Foghorn Therapeutics Inc. furnished a new investor presentation dated September 2025 as an exhibit to a current report. The company plans to use this presentation in meetings and presentations with investors, offering an overview of its business and outlook in a slide format.

The investor materials are provided under a Regulation FD disclosure, which means they are being made available to the public to ensure fair access to information. The company states that the presentation is being furnished, not filed, so it is not subject to certain legal liabilities under the securities laws unless specifically incorporated into other documents.

8-K Event Classification

2 items: 7.01, 9.01

2 items

Item 7.01 Regulation FD Disclosure Disclosure

Material non-public information disclosed under Regulation Fair Disclosure, often investor presentations or guidance.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, and exhibit attachments filed with this report.

Understanding 8-K Material Events →

false000182246200018224622025-09-022025-09-02

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

________________________

FORM 8-K

________________________________________________________________________________________________

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): September 2, 2025

________________________________________________________________________________________________

Foghorn Therapeutics Inc.

(Exact name of registrant as specified in its charter)

________________________________________________________________________________________________

Delaware

001-39634

47-5271393

(State or other jurisdiction of incorporation)

(Commission File Number)

(IRS Employer Identification No.)

500 Technology Square, Ste 700

Cambridge,

MA

02139

(Address of principal executive offices)

(Zip Code)

(Registrant’s telephone number, including area code): (617) 586-3100

Not Applicable

(Former name or former address, if changed since last report)

________________________

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:  

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Trading Symbol(s)

Name of each exchange on which registered

Common Stock, $0.0001 par value per share

FHTX

The Nasdaq Global Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 7.01 Regulation FD Disclosure.

Foghorn Therapeutics Inc. (the “Company”) is furnishing as Exhibit 99.1 to this Current Report on Form 8-K a presentation dated September 2025, which the Company intends to use in meetings with or presentations to investors.

The information in this Item 7.01 (including Exhibits 99.1) is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any filing by the Company under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.

Item 9.01    Financial Statements and Exhibits.

(d) Exhibits

Exhibit No.			Description
99.1			Investor Presentation dated September 2025

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

			FOGHORN THERAPEUTICS INC.
			By:						/s/ Kristian Humer
									Kristian Humer
									Chief Financial Officer

Date: September 2, 2025

FAQ

What did Foghorn Therapeutics (FHTX) disclose in this 8-K?

Foghorn Therapeutics Inc. furnished an investor presentation dated September 2025 as Exhibit 99.1, which it intends to use in investor meetings and presentations.

Is the Foghorn Therapeutics investor presentation considered filed with the SEC?

No. The company specifies that the information in Item 7.01, including Exhibit 99.1, is being furnished and not deemed filed for purposes of Section 18 of the Exchange Act.

Under which SEC item did Foghorn Therapeutics provide the presentation?

The investor presentation was provided under Item 7.01, Regulation FD Disclosure, which is used to share information broadly with investors to promote fair disclosure.

What exhibit is included with this Foghorn Therapeutics (FHTX) 8-K?

The 8-K includes Exhibit 99.1, described as an Investor Presentation dated September 2025.

Does this Foghorn Therapeutics 8-K report any new financial results?

The 8-K focuses on furnishing an investor presentation. It does not describe specific financial results within the text provided.